RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Liabilities
Everything the company owes to creditors and other parties.
RenovoRx, Inc.NASDAQ: RNXT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 5.5% from a year ago
Total liabilities stood at $2.7M at the end of Q1 FY2026, down 5.5% from a year earlier and up 1.0% from the prior quarter. Over 3 fiscal years it compounded at +34.4% a year.
Context
- Total liabilities amounted to 19.3% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -5.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.67M USD
- Year-over-year change
- -26.6%
- 4-year CAGR
- +29.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.67M | -26.6% |
| FY2024 | 2024-12-31 | 3.64M | -18.5% |
| FY2023 | 2023-12-31 | 4.47M | +305.3% |
| FY2022 | 2022-12-31 | 1.1M | +17.5% |
| FY2021 | 2021-12-31 | 938K | — |
Total Liabilities vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total liabilities of $2.7M is the lowest of the 6 companies compared; the peer median is $10.38M.
- Its year-over-year change of -5.5% is the 4th highest of 6, against a peer median of +9.2%.
- Total liabilities amounts to 19.3% of total assets for RNXT, versus a peer median of 54.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $145.39M | +17.4% | -10.4% | 135.5% | |
| Mar 2026 | $13.12M | +388.9% | -18.1% | 80.8% | |
| Mar 2026 | $10.38M | -38.1% | -17.4% | 54.2% | |
| Mar 2026 | $7.56M | +9.2% | +27.8% | 21.4% | |
| Mar 2026 | $3.78M | -12.6% | +1071.7% | 52.3% | |
| Mar 2026 | $2.7M | -5.5% | +34.4% | 19.3% | |
| Peer median (excluding RNXT) | $10.38M | +9.2% | -10.4% | 54.2% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.